Newly Created Form Bio Raises $30M Series A Funding Led by JAZZ Venture Partners to empower life scientists with a complete platform for managing large datasets, executing verified workflows, ...

AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...

"Form Bio is at the forefront of a revolution in how new genetic medicines are discovered and developed," said Dr. Michelle Chen, CEO of Form Bio. "The opportunity to lead this next chapter, scaling ...

Colossal Bio, a biotech trying to resurrect the woolly mammoth, just spun out its first company. The new company, Form Bio, sells manufacturing software to life sciences companies. Insider got the ...

In the midst of an ongoing growth strategy, Form Bio hired Mark Swendsen as Chief Revenue Officer. The computational life sciences platform company, which officially launched late last month, is ...

As companies aim to cut costs and reel in spending amid uncertain macroeconomic conditions, Form Bio thinks it is actually the perfect time to launch its platform. The software company was developed ...

When George Church, PhD, and co-founders established Colossal Biosciences, they envisioned applying their advancements in CRISPR gene editing to the loss of biodiversity, species preservation, and ...

SAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate ...

DALLAS (August 9, 2023) — Form Bio, the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023. The company’s ...

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. This partnership brings together GENEWIZ's industry-leading ...

Partnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular ...